ArticleAnnals of medicine and surgery (2012)2026
DCBLD1 as a novel prognostic biomarker and therapeutic target in breast cancer: clinical validation and mechanistic insights.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the expression of DCBLD1 (discoidin, CUB, and LCCL domain-containing protein 1) in breast cancer tissues and its correlation with patient prognosis, and evaluate its potential as a novel prognostic marker and therapeutic target. Methods: Differential expression of DCBLD1 between breast cancer and normal tissues was analyzed using GEO and METABRIC databases, combined with survival analysis and Cox multivariate regression analysis to evaluate its prognostic value. Effective interference sequences were screened using quantitative polymerase chain reaction, and knockdown efficiency was validated by quantitative reverse transcription polymerase chain reaction and Western blot. The effects of DCBLD1 on breast cancer cell proliferation, apoptosis, migration, and invasion were investigated using CCK-8, flow cytometry, Transwell migration and invasion assays, and wound healing assays. Results: DCBLD1 was significantly overexpressed in breast cancer tissues ( Conclusion: DCBLD1 exhibits oncogene functions in breast cancer and can serve as an independent prognostic marker and potential therapeutic target, with its expression level closely correlated to tumor malignancy and metastasis risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.